Aurora kinase A has been demonstrated to be involved in the malignant progression of many types of cancer including prostate cancer, we therefore hypothesized that Aurora kinase A might work as a valuable target for prostate cancer treatment. To test this hypothesis, we used DNAzyme technology to inhibit Aurora kinase A expression and evaluated the effects of DNAzymes as therapeutic agents to treat prostate cancer. In an in vitro cleavage assay, we found that a DNAzyme (DZ2) targeting Aurora kinase A could effectively cleave Aurora kinase A mRNA. When transfected into the prostate cancer cell line PC3, DZ2 was found to strongly inhibit the expression of Aurora kinase A examined by western blot analysis, and thus suppressed cell growth, arrested the progression of cell cycle, induced cell apoptosis and attenuated cell migration, as measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium assay, flow cytometry and Boyden chamber assay. Through in vivo study, we also found that DZ2 could significantly inhibit the growth of human prostate cancer xenografts in nude mice. In conclusion, DZ2 could effectively attenuate malignant progression of prostate cancer both in vitro and in vivo, suggesting that DNAzyme targeting Aurora kinase A may be used as a valuable therapy to treat prostate cancer.
Introduction
Aurora kinases, a highly conserved kinase family members in eukaryotes, are involved in the processes of cell division. 1 Up till now, three Aurora kinases, A, B and C, have been identified in humans. 2 Among the three kinases, Aurora kinase A is a key kinase that is important in chromosomal distribution. Aurora kinase A amplification and upregulation can induce chromosomal instability leading to aneuploidy and cell transformation in several types of cancer. 3 Prostate cancer is the most common solid tumor malignancy that severely influences quality of life. However, the treatment for prostate cancer remains challenging. Surgery is most often the recommended treatment for young men but radical prostatectomy can cause significant urinary side effects. Therefore, finding effective biochemical treatments for prostate cancer remains interesting.
Recently, Aurora kinase A has been demonstrated to be involved in prostate cancer progression. 4, 5 Furthermore, our previous work demonstrated that Aurora kinase A upregulation was closely associated with malignant phenotypes of prostate cancer. 6 Therefore, Aurora kinase A may be very important in the carcinogenesis of prostate cancer, which means that Aurora kinase A may be a good target for prostate cancer therapy.
DNAzymes have emerged as a new class of nucleic acid-based gene silencing agent. 7 DNAzymes are singlestranded DNA catalysts which can be engineered to bind to their complementary sequence in a target messenger RNA (mRNA) through Watson-Crick base pairing. After binding to a target mRNA, DNA catalysts can cleave the target mRNA at predetermined phosphodiester linkages. 8 These mRNA cleavages by DNA catalysts have been demonstrated as a potential new class of drugs to inhibit gene expression due to the low cost of synthesis, high stability and flexible rational design features of DNAzymes. 9 In the present study, we designed DNAzymes targeting human Aurora kinase A mRNA and tried to determine their effects on human prostate cancer progression both in vitro and in vivo.
Materials and methods

Cell line and nude mice
Prostate cancer cell line PC3 was obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). PC3 cells were routinely maintained in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal bovine serum and incubated in a humidified atmosphere of 5% CO 2 at 37 1C. Cells were passaged routinely by washing with phosphate-buffered saline (PBS; pH 7.4) and trypsinization.
BALB/C nude mice weighing 20 g on average were bought from the Institute of Antibiotics, Sichuan Province (Chengdu, China). Mice were fed ad libitum in a 12/12 h day/night cycle and kept in a constanttemperature environment, sound insulated and air filtered.
Design and synthesis of DNAzymes
Two DNAzymes were designed according to the specific rule of 10-21 DNAzyme. 10 Each DNAzyme targeting Aurora kinase A mRNA contains a catalytic domain of 15 highly conserved deoxyribonucleotides flanked by two substrate-recognition domains, which can cleave effectively between unpaired purine and pyrimidine of mRNA transcripts. Both DNAzymes were synthesized from Roche (Indianapolis, IN, USA). Meanwhile, two inactive DNAzymes with a single nucleotide substitution in the reaction loop (underlined) each, were synthesized as controls. The sequences of human Aurora kinase A mRNA templates and corresponding DNAzymes were as follows (arrow indicated the cleavage point):
Template Cloning of Aurora kinase A cDNA Homo sapiens partial coding sequence for Aurora kinase A was obtained from Genbank (accession no. AF011468). Primers were designed according to the sequence based on Premier 5.0 software. RT-PCR was used to clone the conserved fragment of Aurora kinase A cDNA. Total RNA was isolated from prostate cancer cell line PC3 using TRZ REAGENT (Sigma, St Louis, MO, USA) according to the manufacturer's instructions. First-strand cDNA synthesis was carried out from RNA isolated from PC3 cells using reverse transcriptase (Omniscript, Qiagen, Hilden, Gemany). Each 20 ml of reaction contained 500 mM deoxyribonucleotide triphosphate, 1 mM random decamers, 1 U reverse transcriptase and 3 mg of total RNA. The reaction was conducted at 37 1C for 60 min and then 92 1C for 10 min to end the reaction. The PCR reactions were performed using a PCR Kit (Ampli-Taq 0 . The 341-bp PCR product (325-bp Aurora kinase A cDNA and 16-bp restriction endonuclease enzyme recognizing sequence and 4-bp protective nucleotides) was purified, sequenced and subcloned into pcDNA3.1( þ ) plasmid between the EcoRI and XhoI sites which was named pcDNA3-Aurora kinase A.
In vitro cleavage assay
The recombinant plasmid pcDNA3-Aurora kinase A was linearized by digesting with XhoI. Aurora kinase A mRNA template was synthesized using T7/SP6 in vitro transcription kit (Roche). DIG-UTP was used for in vitro transcription to label the RNA templates with digoxigenin (DIG). The size of DIG-labeled Aurora kinase A RNA was 416 bp (325 bp of Aurora kinase A RNA with 91 bp of plasmid sequence). Aurora kinase A mRNA and DNAzyme were mixed up at molar ratio of 1:100 in 20 ml of reaction buffer containing 50 mmol l À1 Tris-HCL, pH 7.2, 15 mM MgCl 2 , 0.01% SDS. After incubation at 40 1C for 2 h, 96% formamide and 0.1% bromophenol blue in 20 mmol l À1 EDTA were used to stop the reaction. The reaction products were denatured at 95 1C for 8 min, cooled down on ice and then separated on 8 mmol l À1 urea and 8% polyacrylamide gel and transferred to the nylon membrane. The fragments of RNA signals in the reaction products were tested using the DIG luminescence detection kit (Roche) according to the manufacturers' instructions. NIH image was used to measure the densities of the bands signals on X-ray films after scanning and the in vitro cleavage ratio was counted.
Western blot analysis
In vitro cleavage assay showed DZ2 was more effective to cleave Aurora kinase A RNA. We then detected DZ2 inhibition activity of Aurora kinase A in PC3 cells. Cells were grown in 100 mm plates in DMEM supplemented with 5% fetal bovine serum. After cells were 70% confluent, 300 nmol l À1 DZ2 was transfected into cells through FuGENE 6 transfection reagent (Roche) according to the manufacturer's instructions. Meanwhile, DZ1 and inactive DZ2 were transfected into cells as controls. At 24 and 48 h after the transfection, the cells were collected and proteins were detected by western blot. Briefly, cell lysates were prepared by suspending cell pellets in lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP40, 0.5% DOC, 0.1% SDS) including proteinase inhibitors (1 mg ml À1 aprotinin, 1 mg ml À1 leupeptin, 1 mM phenylmethylsulphonyl fluoride). Protein concentration was measured using DcProtein Assay Kit (Bio-Rad, Hercules, CA, USA). Equal amounts of protein (40 mg) were loaded onto an SDS-polyacrylamide gel for electrophoresis and then transferred to polyvinylidene fluoride membrane (Amersham, Piscataway, NJ, USA). The membrane was then incubated with primary anti-bodies for 1 h at room temperature. After washing with Tris-buffered saline Tween 20 (TBS-T), the membrane was incubated with corresponding horseradish peroxideconjugated secondary antibodies (Amersham) and the signals were visualized by ECL (Amersham). The primary antibodies used included anti-BTAK/Aurora A antibody to detect Aurora kinase A (1:800; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-AURKB polyclonal antibody to detect Aurora kinase B (1:1000, LifeSpan Biosciences, Seattle, WA, USA), anti-IPL-1/STK13/ Aurora C antibody to detect Aurora kinase C (1:800; Abcam, Cambridge, MA, USA), anti-active caspase-3 to detect phosphorylated caspase-3 (1:1000; Chemicon International, Temecula, CA, USA), anti-Myc antibody to detect c-Myc (1:800 dilution; Santa Cruz Biotechnology) and anti-human telomerase reverse transcriptase (hTERT) antibody to detect hTERT (1:300; Calbiochem, San. Diego, CA, USA). NIH image was used to measure the densities of the protein signals, and the protein levels were normalized to b-actin as an internal control. A dosedependent assay was also performed. PC3 cells were transfected with DZ2 at various concentrations ranging from 0 to 500 nmol l
À1
. Expression of Aurora kinase A 24 h after the transfection was detected by western blot as described above.
Detection of telomerase activity
Telomerase activities were quantitated using telomerase polymerase chain reaction enzyme-linked immunosorbent assay kits (TRAP-PCR Elisa kit, Boehringer Mannheim, Mannheim, Germany) according to the manufacturer's instruction. Briefly, 48 h after the treatment described above, PC3 cells were lysed and the lysates were used to perform the primer extension and amplification reaction in the presence of the biotin-labeled primers. Amplification products were immobilized on streptavidin-coated microplate and hybridized to a DIG-labeled probe specific for the telomeric repeats. Finally, the DIG-labeled hybrids were visualized with a peroxidase-conjugated anti-DIG antibody and a colorimetric peroxidase substrate. Telomerase activities were determined in triplicate and negative controls provided by the TRAP-PCR Elisa Kit were run each time. The sample absorbance at 450 nm measured using an ELISA reader represents telomerase activity. In addition, a telomeric repeat amplification protocol assay was also performed using a TRAPeze Telomerase Detection Kit (Intergen, New York, NY, USA) as described previously. Cell proliferation detected by MTT assay MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium) assay was conducted to determine cell proliferation. A total of 2 Â 10 3 cells in 100 ml of the medium were plated in 96-well plates, and 100 nmol l À1 DZ2 was transfected through FuGENE 6 every 24 h up to 7 days, inactive DZ2 was transfected as the control. Each day 20 ml of 5 g l À1 MTT (Sigma, St Louis, MO, USA) solution was added to each well and incubated for 4 h in a 37 1C incubator. Then 150 ml of dimethyl sulfoxide (Sigma) was added to dissolve the crystal after the growth medium was removed. The absorbance of 200 ml solution from each well was measured at 570 nm by a microplate reader. Each sample was assayed in octuple for 7 days consecutively. Cell growth curves were obtained based on the corresponding values of OD 570 .
Cell-cycle distribution detected by flow cytometry Downregulation of Aurora kinase A has been shown to cause disruption of cell-cycle transition with delay in mitotic entry in other kinds of mammalian cells. 12 To determine this possibility in PC3 cells, cell-cycle distribution was detected using flow cytometry. Briefly, 300 nmol l À1 DZ2 was transfected through FuGENE 6 into PC3 cells, 12, 24 and 48 h after the treatment, cells were collected and washed with PBS, and then suspended in Krishan buffer (0.1% sodium citrate, 0.2 mg ml À1 RNAase, 0.3% NP40) containing 0.05 mg ml À1 propidium iodide and incubated at 4 1C for 30 min, finally cells were subjected to Coulter flow cytometry for analysis. Data were analyzed using ModFitLT 2.0 (Verity Software House, Topsham, ME, USA). Inactive DZ2 was added to perform a similar treatment as the negative control.
In vitro migration assay
We next investigated the capacity of DZ2 to influence PC3 cell migration. Cells (1 Â 10 6 ) were transfected with 300 nmol l À1 DZ2 or inactive DZ2 through FuGENE 6. After 24 h, Boyden chamber (Neutroprobe, Bethesda, MD, USA) was used to detect cell migration. Briefly, cells were harvested by trypsinization, counted and resuspended in DMEM at a concentration of 1 Â 10 5 ml À1 , then 0.5 ml aliquots of cell suspension were added to the upper chamber. The upper and lower chambers were separated by a 12 mm pore polycarbonate membrane that was coated with Matrigel. After 24 h of incubation at 37 1C, the remaining cells on the upper side of the chamber were carefully scraped off with a cotton swab. Cells migrating through the pores to the bottom side of the membrane were fixed with 3.7% paraformaldehyde and stained with hematoxylin and eosin. The number of migrating cells was counted in 10 randomly selected fields under microscope.
Tumor xenograft mouse models These studies were approved by the Animal Care and Ethics Committee of Sichuan University. In total, 12 male and 12 female BALB/C nude mice, 5 weeks of age with average weight of 20 g, were housed in separate cages. PC3 cells were subcutaneously transplanted into each mouse. After 5 weeks, the tumor tissues had increased to a volume of about 65 mm 3 and were ready to use for the following experiments. Nude mice were assigned to three groups, each group consisting of four males and four females. The first group serving as control received equal volume (10 ml) of normal saline injection but no DNAzyme treatment. Each mouse in the second group was injected with 8 mg of DZ2 (dissolved in 10 ml saline) into the tumor tissue every day by multipoint intratumorally injection. Each mouse in the third group received 8 mg of inactive DZ2 (dissolved in 10 ml saline) in the same way as Effects of Aurora A DNAzymes on prostate cancer Y Qu et al the other two groups. Tumor volumes were assessed using digital Vernier callipers daily in a blinded way. After 14 days of daily injection, mice in each group were decapitated. The body weight of the mice and the wet weight of the tumors were measured. The tumor tissues were then collected to determine the expressions of Aurora kinase A and active caspase-3 using western blot analysis, and telomerase activity was also detected as described above.
Statistics
Data are presented as means±s.d. Statistical analyses were carried out by the analysis of variance. P-value of o0.05 was taken as the limitation of significance.
Results
In vitro cleavage of Aurora kinase A transcripts by DNAzymes We designed two 10-23 DNAzymes named DZ1 and DZ2, respectively, and tested the efficacy of the DNAzymes to cleave the mRNA substrate of Aurora kinase A. DIG-labeled Aurora kinase A mRNA obtained through in vitro transcription was mixed with DNAzymes at molar ratio of 1:100 to perform in vitro cleavage reaction at 40 1C for 2 h. The cleaved fragments were separated on a urea denaturing polyacrylamide gel and tested by detecting the DIG luminescence. Theoretically, the 416 bp Aurora kinase A fragment would be cleaved to 320 and 96 bp fragment by DZ1, but 292 and 124 bp by DZ2. As a result, DZ2 showed more effective cleavage activity against human Aurora kinase A RNA than DZ1. The in vitro cleavage ratio of DZ2 equals ((densities of 292 bp band) þ (densities of 124 bp band))/total densities of 416 292 and 124 bp bands) Â 100%, which reached about 64%. However, inactive DNAzymes could not cleave Aurora kinase A RNA (Figure 1 ).
Inhibition of Aurora kinase A in PC3 cells by DZ2
To investigate whether DZ2 could inhibit Aurora kinase A in prostate cancer cell line PC3, 300 nmol l À1 DZ2 was transfected into cells through FuGENE 6 transfection reagent. Meanwhile, DZ1 and inactive DZ2 were transfected into cells as controls. At 24 and 48 h after the transfection, cells were collected and proteins were detected by western blot. We found that in PC3 cells, DZ2 significantly inhibited the expression of Aurora kinase A compared with DZ1 and inactive DZ2 (Figure 2a) . Furthermore, the suppression of Aurora Figure 1 In vitro cleavage of Aurora kinase A transcripts by DNAzymes. A conserved fragment of Aurora kinase A cDNA was obtained through RT-PCR and cloned into the pcDNA3 plasmid to create a recombinant plasmid pcDNA3-Aurora A. Digoxigenin (DIG)-labeled Aurora kinase A mRNA was obtained through in vitro transcription of plasmid pcDNA3-Aurora A and mixed with DNAzymes at molar ratio of 1:100 to perform in vitro cleavage reaction at 40 1C for 2 h. The reaction products were separated through urea denaturing polyacrylamide gel electrophoresis and the fragments were tested by the DIG-luminescence method. This experiment was repeated three times and representative results were shown. As a result, DZ2 showed a stronger cleavage activity against human Aurora kinase A RNA used as template than DZ1, the in vitro cleavage ratio reached about 64%. However, the inactive DNAzymes could not cleave Aurora kinase A RNA. ) was transfected into cells through FuGENE 6 transfection reagent. Meanwhile, DZ1 and inactive DZ2 were transfected into cells as controls. At 24 and 48 h after the transfection, the cells were collected and Aurora kinase A protein level was detected by western blot. This experiment was repeated four times and representative results were shown. NIH image was used to measure the densities of the protein signals, and the protein levels were normalized to b-actin as an internal control. Data from four independent experiments were statistically analyzed by analysis of variance (ANOVA). *Compared with no treatment, DZ1 or inactive DZ2 group, Po0.05. (b) Dose-dependent knockdown of Aurora kinase A expression by DZ2. PC3 cells were transfected with DZ2 at various concentrations ranging from 0 to 500 nmol l
À1
. Expression of Aurora kinase A 24 h after the transfection was detected by western blot. b-Actin expression was monitored as the control. The ratio of Aurora kinase A/b-actin was calculated by using densitometry, and values were normalized by dividing the ratio at no treatment (0 nmol l
) and termed as relative Aurora kinase A level. This experiment was repeated four times and representative results were shown. (c) Western blot analysis. DZ2 (300 nmol l À1 ) was transfected into PC3 cells through FuGENE 6 transfection reagent. Meanwhile, DZ1 and inactive DZ2 were transfected into cells as controls. Forty-eight hours after the transfection, the cells were collected and Aurora kinases B and C, c-Myc, human telomerase reverse transcriptase (hTERT) and active caspase-3 levels were detected by western blot. This experiment was repeated three times and representative results were shown. (d) Detection of telomerase activity. Forty-eight hours after the treatment described above, telomerase activities were quantitated by TRAP-PCR Elisa kits in triplicate and negative controls (NC) provided by the TRAP-PCR Elisa Kit were run each time. The sample absorbance at 450 nm measured using an ELISA reader represents telomerase activity. Data presented as means ± s.d. Statistical analyses were performed by ANOVA. *Compared with no treatment, DZ1 or inactive DZ2 group, Po0.05. In addition, a telomeric repeat amplification protocol (TRAP) assay was also performed using a TRAPeze Telomerase Detection Kit, IC indicated internal control for Taq amplification of telomere extension products.
Effects of Aurora A DNAzymes on prostate cancer Y Qu et al kinase A protein was achieved in a dose-dependent manner when the concentration of DZ2 was less than 300 nmol l À1 . However, more DZ2 than 300 nmol l
could not enhance the suppression of Aurora kinase A anymore (Figure 2b ). Meanwhile, we examined the selectivity of DZ2 and found that DZ2 did not cause a nonspecific inhibition of Aurora kinase B and C (Figure 2c) .
To investigate the mechanism by which DZ2 inhibits the malignant phenotypes of PC3 cells, we detected active caspase-3 and potential downstream proteins of Aurora kinase A. Forty-eight hours after DZ2 treatment, the active caspase-3 was obviously increased, but the expression of c-Myc and hTERT was downregulated in PC3 cells (Figure 2c) . Accordingly, the telomerase activities were significantly attenuated by DZ2 (Figure 2d) .
Inhibition of PC3 cell proliferation by DZ2
To investigate whether DZ2 could inhibit prostate cancer cell growth in vitro, we carried out cell proliferation assay using PC3 cells. In total, 100 nmol l À1 DZ2 was transfected through FuGENE 6 every 24 h, and cellular proliferation was monitored by MTT assay daily for 7 days. Compared with the untreated or inactive DZ2-treated group, DZ2 decreased cell proliferation significantly. Whereas there was no difference of proliferation between untreated group and inactive DZ2 group. These results indicated that DZ2 had the potency to inhibit cell proliferation in PC3 cells and there was no obvious toxicity of oligonucleotides to treat PC3 cells (Figure 3 ).
DZ2 induced cell-cycle arrest and cell apoptosis
To study if suppression of Aurora kinase A would attenuate cell-cycle transition in PC3 cells, we measured cell-cycle distribution using flow cytometry. We found that inhibition of Aurora kinase A via DZ2 induces cellcycle arrest and apoptosis. In DZ2-treated cells, the percentage of cells in G 2 -M was increased to around 14.23% at 12 h, 21.02% at 24 h and 29.56% at 48 h. However, in inactive DZ2-treated cells, the percentage of cells in G 2 -M was approximately 9.56% at each time point. In addition, we found that a fraction of cells in sub-G 1 phase of the cell cycle (indicating apoptotic cells) in the DZ2-treated cells was significantly increased compared to the control-treated cells (Figure 4 ). These results indicated that DZ2-mediated suppression of Aurora kinase A led the PC3 cells to abnormal accumulation in the G 2 -M phase and to eventual apoptosis.
DZ2 inhibited cell migration in vitro
To investigate whether DZ2 could inhibit migration of prostate cancer in vitro, cell migration of PC3 cells was examined using the Boyden chamber assay system. PC3 cells were transfected with 300 nmol l À1 DZ2 or inactive DZ2 through FuGENE 6. After 24 h, Boyden chamber was used to detect cell migration. We evaluated PC3 migration from the upper to the lower chamber 24 h after cell seeding. We found that DZ2 significantly inhibited PC3 migration, whereas the number of cells migrating to the lower chamber in the inactive DZ2 group did not differ from no-treatment control ( Figure 5 ). Figure 3 Inhibition of prostate cancer cell PC3 growth by DZ2. DZ2 (0.1 mM) was transfected through FuGENE 6 every 24 h into PC3 cells. Meanwhile, inactive DZ2 was transfected into cells as the control. Cellular proliferation was monitored by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay daily for 7 days. Cell growth curves were obtained based on the corresponding values of OD 570 . This experiment was repeated four times and data were statistically analyzed by analysis of variance (ANOVA). It showed that DZ2 inhibited cell proliferation significantly, whereas inactive DZ2 had no obvious inhibitory effect on cell proliferation, indicating that DZ2 had the potency to inhibit cell proliferation in PC3 cells and there was no obvious toxicity of oligonucleotides to treat PC3 cells. Data presented as means±s.d. Statistical analyses were performed by ANOVA. *Compared with the untreated and inactive DZ2 group, Po0.05. Figure 5 DZ2 inhibits PC3 migration. DZ2 (0.3 mM) was transfected into PC3 cells through FuGENE 6. Meanwhile, inactive DZ2 was transfected into cells as the control. After 24 h, Boyden chamber was used to detect cell migration. We evaluated PC3 migration from the upper to the lower chamber 24 h after cell seeding. Cells migrating through the pores to the bottom side of the membrane were fixed and stained with hematoxylin and eosin. The number of migrating cells were counted in 10 randomly selected fields under microscope. The data (mean ± s.d.) were representative of at least two independent experiments performed in triplicate, and statistically analyzed by the analysis of variance (ANOVA). It showed that DZ2 significantly inhibited PC3 migration, whereas the number of cells migrating to the lower chamber in the inactive DZ2 group did not differ from no treatment control. *Compare DZ2 group and inactive DZ2 group, Po0.05. 3 , DNAzymes (DZ2 or inactive DZ2, 8 mg) in 10 ml saline or 10 ml saline alone were injected into the tumor tissue every day by multipoint intratumorally injection for 14 days. We found that DZ2 obviously inhibited the growth of human prostate cancer cells as solid tumors in athymic nude mice, whereas inactive DZ2 showed no effect to inhibit tumor growth (Figures 6a and b) . Throughout the study, animals did not exhibit signs of discomfort due to tumor growth, the body weights of the mice were not adversely affected by oligonucleotide administration (Figure 6c ). It also showed that DZ2 significantly inhibited Aurora kinase A expression in tumor tissues (Figure 6d) , which was paralleled with downregulation of telomerase activity (Figure 6e) . However, the active caspase-3 in tumor tissues was increased (Figure 6a ). 
Discussion
Aurora kinase A is a centrosome-associated kinase, which functions in centrosome maturation and spindle assembly and is thus physiologically essential for proper segregation of chromosomes into daughter cells. 13 However, abnormal Aurora kinase A expression will induce chromosomal instability leading to aneuploidy and cell transformation.
14 Previous studies have demonstrated that Aurora kinase A upregulation was involved in the malignant progression of many types of cancers including prostate cancer, [3] [4] [5] suggesting that Aurora kinase A may be a valuable target for treatment of prostate cancer. The DZ2 was designed targeting to the 5 0 nonconserved region of Aurora kinase A mRNA, which showed a strong ability to inhibit the expression of Aurora kinase A, without nonspecific inhibition of Aurora kinase B and C. It is not very clear whether Aurora kinases A or B is the better target for oncology therapy. Because the major phenotype with pan-Aurora kinase small molecules is consistent with Aurora kinase B inhibition, the validity for targeting Aurora kinase A as an anticancer therapeutic approach has been questioned. 15 Our findings with DZ2 demonstrated that inhibition of Aurora kinase A alone could effectively inhibit malignant progression of prostate cancer both in vitro and in vivo. The usage of Aurora kinase A-specific inhibitors other than pan-Aurora kinase inhibitors for prostate cancer treatment may minimize potential toxic effects.
We analyzed the phenotypes of cultured prostate cancer cells (PC3) after DZ2-mediated Aurora kinase A knockdown. We found that inhibition of Aurora kinase A with DZ2 could inhibit cell proliferation, arrest the progression of cell cycle, induce cell apoptosis and attenuate cell migration in cultured PC3 cells. The mechanisms of how Aurora kinase A knockdown attenuates malignant phenotypes are not fully clarified. Previous findings implicate Aurora kinase A as an important regulator of both genomic integrity and cell-cycle progression. 14, 16 Aurora kinase A can phosphorylate targeted proteins that is important in regulating genomic integrity and cell mitosis such as histone H3, 17 22 and so on. Under normal physical conditions, Aurora kinase A will maintain the dynamics of cell mitosis. However, the upregulation of Aurora kinase A in cancer cells will drive genomic instability and speeding up cell mitosis. 14, 16 In addition, recent work has demonstrated that Aurora kinase A can upregulate the expression of oncogenes such as telomerase, c-myc and P53, and overexpression of these proteins will enhance cell proliferation and inhibit cell apoptosis, which might be an another major mechanism for Aurora kinase A contributing to carcinogenesis. 23 In this study, we found that DZ2 significantly downregulated the expression of c-Myc and hTERT, and thus inhibited telomerase activity both in cultured PC3 cells and in xenograft tumors, suggesting that telomerase inhibition might be involved in attenuating the progression of prostate cancer. However, we found that cell apoptosis occurred as early as 48 h after DZ2 treatment, which is not consistent with the time point of cell death resulted from telomerase inhibition, for the latter is mainly triggered by telomere catastrophe and occurs heavily at the later culture stages. 24 Therefore, cellular apoptosis found in this study might not be entirely contributed by telomerase inhibition, suggesting that there are different mechanisms contributing to cell death after Aurora kinase A knockdown. Up till now, little is known about the relationship between Aurora kinase A and cell migration. Recently, Wu et al. 25 reported that Aurora kinase A promoted collagen I induced cell motility in epithelial cells, suggesting a promoting role for Aurora kinase A in migrating epithelium. Another report showed that Aurora kinase A increased cell migration and this function was correlated with Akt1 activation in laryngeal cancer cells. 26 In this study, we found that inhibition of Aurora kinase A could decrease PC3 cell migration, which further proved the important role of Aurora kinase A in regulating cell migration.
In in vivo study, we found that inhibition of Aurora kinase A with DZ2 significantly inhibited PC3 tumor growth in nude mice, without obvious adverse effects. Previous reports showed that Aurora kinase A was largely upregulated and amplified in tumor organs and cells compared with normal organs and cells, 14, 27 indicating that inhibitors targeting Aurora kinase A would have some selectivity for tumor cells versus normal cells, suggesting that inhibitors targeting Aurora kinase A can be used to treat cancers with low risk of adverse effects. Our results in this study proved this hypothesis.
Up till now, many inhibitors against Aurora kinase A have been developed such as VX-680, 28 MLN8054 29 and Aurora A RNAi. 30 However, our first time report is to demonstrate that DNAzyme-mediated knockdown of Aurora kinase A can be used as a specific gene-targeting therapy to suppress progression of prostate cancer. A handful of studies have shown the potential of DNAzymes against cancer both in cell culture and in vivo models, 31 suggesting that DNAzymes would become powerful therapeutics of cancer in the future. In our present study, although DZ2 effectively suppressed prostate cancer growth, it could not inhibit Aurora kinase A expression and cancer growth absolutely. To improve the cleavage ability of DZ2 and enhance its delivery ratio into solid tumor remain questions to be solved. As we have shown, knockdown of Aurora kinase A by DZ2 decreased migration in cultured PC3 cells. Whether DZ2 could suppress metastasis of prostate cancer xenografts in nude mice needs further investigation.
